Exact Sciences (EXAS) reported a Q4 net loss late Friday of $0.45 per diluted share, narrowing from a loss of $4.67 a year earlier.
Analysts polled by FactSet expected a loss of $0.11.
Revenue in the three months ended Dec. 31 rose to $878.4 million from $713.4 million a year earlier.
Analysts polled by FactSet expected $860.9 million.